




FOUNDATION FOR  
**Women & Girls**  
with Blood Disorders  
*presents*

# Uterine Hemostasis Colloquium IV: Hemostatic Disorders in Women & Girls

March 9 - 10, 2023 | Orlando, Florida

*Colloquium Program*



# Uterine Hemostasis Colloquium IV: Hemostatic Disorders in Women & Girls

Thursday, March 9<sup>th</sup> to Friday, March 10<sup>th</sup>, 2023 | Orlando, Florida  
Preceding HTRS Scientific Symposium 2023

The Foundation for Women & Girls with Blood Disorders is pleased to host the 2023 national colloquium on uterine hemostasis, convening faculty, researchers, and clinicians to review current practices and evidence-based information on the diagnosis and optimal clinical management of uterine hemostasis among women with bleeding and clotting disorders across the lifespan. The purpose of this meeting is to review current knowledge and practice as applied to 1) approaches to urgent bleeding events, 2) critical bleeding and clotting events through pregnancy and delivery, 3) the management of delivery for women with congenital or acquired blood disorders, with a focus on the prevention and management of postpartum hemorrhage, as well as fetal considerations at time of delivery, and 4) hematologic management through COVID.

## Target Audience

This activity is designed for hematologists, pediatric/adolescent gynecologists, adult OB/GYN providers, nurse practitioners, and other healthcare providers are among the critical audience for this meeting. These providers will directly benefit from increased knowledge and review of critical clotting issues that arise, translating into improved practice. An additional benefit is to emphasize the importance of collaborating with their hematology and gynecology colleagues when caring for women and girls through the reproductive years.

## Learning Objectives

1. Convene top experts in the fields of Obstetrics/Gynecology and in Hematology, who are working in uterine hemostasis and blood disorders in women and girls.
2. Review the state of the science with respect to trauma, fibrinolysis, the complement system, and coagulation pathways.
3. Recognize the range of complications related to COVID and the options for its management in women with blood disorders and during pregnancy.
4. Describe and review the best practices concerning abortion and contraception for women and girls with blood disorders.
5. Examine the full range of options for achieving uterine hemostasis in women with postpartum hemorrhage, and bleeding and clotting disorders including thrombotic microangiopathies.
6. Describe and apply available options for optimally managing care in pregnancies identified to be at-risk for fetal and neonatal alloimmune thrombocytopenia.
7. Discuss approaches in the case of thrombocytopenia in pregnancy, for antenatal interventions and for managing delivery, postpartum care, and the neonate.
8. Develop and disseminate a summary of what was discussed regarding the state-of-the-science in hemostatic disorders in women and girls and identify research gaps.
9. Describe, and underscore for target healthcare providers, the intersection of obstetrics/gynecology and hematology in the optimal care of these women and develop mechanisms for facilitating the collaboration of these specialties.

## Activity Goal

This activity is designed to address the following core and team competencies:

*Patient Care, Medical Knowledge, Employ Evidence-Based Practice, Interprofessional Collaboration and Communication*

## Non-Endorsement

The accredited provider verifies that sound education principles have been demonstrated in the development of this educational offering as evidenced by the review of its objectives, teaching plan, faculty, and activity evaluation process. The accredited provider does not endorse or support the actual opinions or material content as presented by the speaker(s) and/or sponsoring organization.

# Accreditation Overview

## Disclosure

The accredited provider adheres to accreditation requirements regarding industry support of continuing medical education. Disclosure of the planning committee and faculty's commercial relationships will be made known at the activity. Speakers are required to openly disclose any limitations of data and/or any discussion of any off-label, experimental, or investigational uses of drugs or devices in their presentations. - *All employees in control of content have no relevant financial relationships to disclose.* All relevant financial relationships have been mitigated. The following participants have *No Relevant Financial Relationships to Disclose*: Maureen Baldwin, MD, MPH; Lisa Baumann Kreuziger, MD, MS; Kristina Haley, DO, MCR; Arthur Vaught, MD; Alisa Wolberg, PhD.

First	Last	Suffix	Commercial Interest	Role
Richard	Burwick	MD, MPH	Alexion, AstraZeneca Rare Disease UCB Pharma	Speaker's Bureau, Research Grant Global Advisory Board
Andra	James	MD, MPH	Cerus	Consultant
Nigel	Key	MB, Chb, FRCP	Novo Nordisk Biomarin	Chair, Access to Insight Grants Study Section Consultant
Barbara	Konkle	MD	CSL Behring, Takeda Sanofi, Pfizer	Research Grant Research Grant, Consultant
Kenneth	Moise	MD	Janssen Pharmaceuticals, Inc BillionToOne, Inc, Health Management Associates, Inc GLC Healthcare, Inc	Research Grant, Advisory Boards Consultant  Speaker's Bureau
Luis D.	Pacheco	MD	Coagulant Therapeutics	Consultant
Michael	Paidas	MD	Biolncept, LLC	Research Grant, Principal Investigator; Scientific Advisory Board, Stock Option

## Accreditation

In support of improving patient care, this activity has been planned and implemented by Cine-Med and the Foundation for Women & Girls with Blood Disorders. Cine-Med is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



## Physicians

Cine-Med designates this live activity for a maximum of 7 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## Nurses

This activity provides 7 contact hours for nurses.

## Other Healthcare Professionals

All other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for activities designated for *AMA PRA Category 1 Credits™*, consult your professional licensing board.

## Certificates

To claim your CME/CE credits, complete the online Credit and Evaluation form using the following URL: <https://cine-med.com/certificate.php?redirect=uhc2023>. Credits should be tracked at the completion of the program. Participants will be able to download or print a certificate once the form has been submitted.

## Support

This activity is being supported by an educational grant from **Grifols**.

Thursday, March 9<sup>th</sup>, 2023 | 1:00 – 5:00 PM | Crystal Ballroom D

1:00 – 1:10 PM	<b>Welcome</b> <i>Barbara A. Konkle, MD</i>
1:10 – 1:45 PM	<b>Why Is It So Hard to Measure Fibrinolysis?</b> <i>Nigel Key, MB, ChB, FRCP</i> Dr. Key will discuss the role of (hyper) fibrinolysis in selected bleeding disorders including trauma, thrombocytopenia, and heavy menstrual bleeding. He will review the physiology of fibrinolysis and discuss why it has been challenging to incorporate global assays of fibrinolysis into clinical practice. Finally, he will discuss how a greater understanding of the successes and failures of anti-fibrinolytic agents in clinical trials help to inform the contribution of fibrinolysis in acquired bleeding disorders.
1:45 – 2:20 PM	<b>New Methods for Measuring Plasmin Generation: From Mice to Humans</b> <i>Alisa Wolberg, PhD, FAHA</i> Dr. Wolberg will present her work to develop a method to measure plasmin generation in plasma. The talk will cover 1) her work that used genetically-engineered mouse models as tools to characterize this assay, and 2) how her lab applied this assay to advance understanding of plasmin generation in human health and disease settings.
2:20 – 2:30 PM	<b>Discussion and Q &amp; A</b>
2:30 – 2:45 PM	<b>Break</b>
2:45 – 3:45 PM	<b>Lessons in Hemostasis &amp; Thrombosis We Have Learned from COVID-19</b> <ul style="list-style-type: none"><li>• <b>COVID-19 and Coagulation:</b> <i>Michael J. Paidas, MD</i></li><li>• <b>Clinical Care and Guidelines:</b> <i>Lisa Baumann Kreuziger, MD, MS</i></li></ul> Dr. Baumann Kreuziger and Dr. Paidas will discuss lessons learned about hemostasis and thrombosis clinical research, guidelines, and care of patients with COVID-19.
3:45 – 4:00 PM	<b>Discussion and Q &amp; A (short break)</b>
4:00 – 4:45 PM	<b>Abortion &amp; Contraception for Patients with Blood Disorders: A Practical Guide</b> <i>Maureen K. Baldwin, MD, MPH</i> <i>Kristina Haley, DO, MCR</i> This session will be focused on practical approaches to early pregnancy procedures and use of contraceptive products in people with blood disorders. We will discuss hot topics in research for bleeding prophylaxis and management and the implications of the changing legal landscape on access to medical care.
4:45 – 5:00 PM	<b>Final Q &amp; A, Wrap Up for Day 1</b> <i>Barbara A. Konkle, MD</i>



## Friday, March 10<sup>th</sup>, 2023 | 7:00 – 11:00 AM | Crystal Ballroom D

7:00 – 7:30 AM	<b>Breakfast</b>
7:30 – 7:40 AM	<b>Welcome</b> <i>Luis D. Pacheco, MD</i>
7:40 – 8:15 AM	<b>C-5 inhibition of Thrombotic Microangiopathy (TMA) in Pregnancy</b> <i>Richard Burwick, MD, MPH</i> Dr. Burwick will discuss diagnosis and management of thrombotic microangiopathy in pregnancy and the postpartum period. He will review key differences between HELLP syndrome, TTP, and aHUS. Dr. Burwick will focus on complement-mediated TMA and use of C5 inhibitors for treatment of pregnancy-associated aHUS, with a brief discussion of its investigational use for treatment of preeclampsia, HELLP syndrome and COVID-19 in pregnancy.
8:15 – 8:45 AM	<b>Massive Postpartum Hemorrhage: Diagnosis &amp; Treatment</b> <i>Jason Vaught, MD</i> This presentation will be centered around diagnosis, management, and ultimately treatment options for this highly morbid patient population. Additionally, there will be a focus on the maneuvers for blood loss in patients unable to receive blood products (alloimmunization, hyperhemolysis, Jehovah's Witness), and how hematologists can augment treatment and management through expertise in thrombophilias and anticoagulant reversal.
8:45 – 9:15 AM	<b>Life-Threatening Venous Thromboembolism &amp; Pulmonary Embolism During Pregnancy</b> <i>Andra H. James, MD, MPH</i> Dr. James will discuss life-threatening venous thromboembolic events, particularly pulmonary embolism, during pregnancy; goals of treatment; the role of vena cava filters; and the range of treatments from anticoagulation to thrombolysis, thrombectomy and ECMO.
9:15 – 9:30 AM	<b>Bringing the Conversation Together: Discussion</b> <i>Luis D. Pacheco, MD</i>
9:30 – 9:45 AM	<b>Break</b>
9:45–10:15 AM	<b>Red Blood Cell Alloimmunization</b> <i>Kenneth J. Moise, Jr., MD</i> Dr. Moise will present an overview of the evolution in diagnostic methods to detect fetal anemia, $\Delta OD450$ , middle cerebral artery peak systolic velocity and free fetal DNA. He will share the evolution of the treatment of fetal anemia through intrauterine transfusion, the advent of the intraperitoneal transfusion, followed by the intravascular transfusion, and the recent advances in immunotherapy including the use of intravenous immune globulin and clinical trials on FcRN blockade therapy.
10:15–10:45 AM	<b>Fetal &amp; Neonatal Alloimmune Thrombocytopenia (FNAIT)</b> <i>Michael J. Paidas, MD</i> In this presentation, Dr. Paidas will discuss the underlying pathology of NAIT, recognition of when a workup for NAIT should be performed, and how to conduct the appropriate evaluation and provide counseling. Additionally, Dr. Paidas will offer a management strategy to women at risk of having a fetus/neonate with NAIT.
10:45–11:00 AM	<b>Bringing the Conversation Together: Final Wrap-Up</b> <i>Luis D. Pacheco, MD</i>

## Faculty (in alphabetical order)



### **Maureen K. Baldwin, MD, MPH**

Maureen K. Baldwin, MD, MPH, is Associate Professor of Obstetrics and Gynecology at OHSU in Portland, Oregon, where she completed her medical training, including a master's degree in public health and a fellowship in Complex Family Planning. Dr. Baldwin has a Practice Focus Designation in Pediatric and Adolescent Gynecology and is Co-Director of an Interdisciplinary Hematology and Gynecology Adolescent clinic called "Spots, Dots and Clots," which treats teens with heavy menstrual bleeding and clotting disorders. She serves as a Medical Advisor for the National Hemophilia Foundation and the Foundation for Women & Girls with Blood Disorders. Her research has focused on hormonal management of menstruation, pregnancy loss, abortion safety, system approaches to contraceptive access, and teaching with simulation.




### **Lisa Baumann Kreuziger, MD, MS**

Lisa Baumann Kreuziger, MD, MS, is an Investigator at the Blood Research Institute of Versiti and Associate Professor at the Medical College of Wisconsin. She specializes in non-malignant hematology with an emphasis in thrombosis. She is the Medical Director of the Antithrombotic Therapy Management Program at Froedtert Hospital where she leads quality improvement projects involving anticoagulation. Dr. Baumann Kreuziger's research interests involve venous thromboembolism (VTE), device and cancer associated thrombosis. She is the co-founder of the Venous thromboEmbolism Network US (VENUS), a network of clinical investigators focused on VTE research. She serves on the NIH COVID-19 Guideline panel and the ACCP Antithrombotic Therapy for VTE Disease Guideline Panel.



### **Richard Burwick, MD, MPH**

Richard Burwick, MD, MPH, is an Associate Professor and Maternal Fetal Medicine Physician with San Gabriel Valley Perinatal Medical Group in Los Angeles, California. He completed his OB-GYN residency training at UCLA-Harbor, and Maternal Fetal Medicine Fellowship at Brigham and Women's Hospital at Harvard Medical School. Dr. Burwick studies the role of complement proteins in preeclampsia, HELLP syndrome, atypical hemolytic uremic syndrome, and COVID-19. He was principal investigator on clinical trials evaluating complement blockade for the treatment of preeclampsia and severe COVID-19 in pregnancy. He has led multiple complement biomarker studies in the United States and Colombia, and he has over 60 publications in peer-reviewed journals. Dr. Burwick is a full-time clinician, and he consults regularly on high-risk pregnancies, with a special interest in blood and kidney disorders in pregnancy, including pregnancy-associated aHUS.



### **Kristina Haley, DO, MCR**

Kristina Haley, DO, MCR, is the Director of The Hemophilia Center at OHSU. She co-directs the OHSU "Spots, Dots, & Clots Clinic", which is a combined interdisciplinary hematology/gynecology clinic for adolescent women with bleeding and clotting disorders. Dr. Haley spends time educating medical students, residents, and fellows as well as community health care providers on all things non-malignant hematology, with an emphasis on the care of women and girls with blood disorders. Dr. Haley's research includes projects aimed at characterizing the symptoms, treatments, and impacts of bleeding in women with bleeding disorders through a national dataset as well as improving the understanding of platelet disorders.

**Andra H. James, MD, MPH**

Andra H. James, MD, MPH is Professor Emeritus of OB-GYN in Maternal-Fetal Medicine and Consulting Professor of Medicine in Hematology at Duke University. Her research and publications pertain mainly to the care of women with blood disorders during pregnancy. Dr. James is also the founding President of FWGBD, and currently serves on the Board of Directors.

**Nigel Key, MB, ChB, FRCP**

Nigel Key, MB, ChB, FRCP is the Harold R. Roberts Distinguished Professor of Medicine at the University of North Carolina. Dr. Key is Vice-Chief for Research in the Division of Hematology, Director of the UNC Blood Research Center and the UNC Hemophilia and Thrombosis Center. Dr. Key is a graduate of St. Andrews University and the University of Manchester in the UK. After residency training in internal medicine and sub-specialty training in hematology in the UK, he completed a research fellowship before joining the faculty at the University of Minnesota (1988-2005). He was recruited to UNC in 2005, where his clinical practice is entirely in non-malignant hematology. Dr. Key directs a NIH-funded translational research laboratory and participates in clinical trials in hemophilia and other bleeding disorders. He has authored 337 publications and 30 book chapters.

**Barbara A. Konkle, MD**

Barbara A. Konkle, MD, is a Professor of Medicine, Division of Hematology, at the University of Washington and the Research Director at the Washington Center for Bleeding Disorders. Dr. Konkle has long been committed to improving the care of women with bleeding and clotting disorders through research, clinical care, and leadership in national organizations, and is the recipient of the ISTH 2021 Esteemed Career Award. Dr. Konkle is a founding member of FWGBD and currently serves on the Board of Directors.

**Kenneth J. Moise Jr., MD**

Kenneth J. Moise Jr, MD, is Professor of Women's Health at Dell Medical School. He also serves as the Director of the Comprehensive Fetal Care Center at Dell Children's Medical Center in Austin, Texas. Dr. Moise completed his residency in Obstetrics and Gynecology at Vanderbilt University followed by a fellowship in Maternal-Fetal Medicine at Baylor College of Medicine. He is a founding member of the North American Fetal Treatment Network (NAFTNet) having served on its executive board and its steering committee. He is board certified in general Obstetrics and Gynecology as well as Maternal-Fetal Medicine. Dr. Moise's interest in fetal therapy spans a 30-year period. He is recognized world-wide for his contributions in the fetal treatment of Rh disease including the development of middle cerebral artery Doppler for the non-invasive detection of fetal anemia and the use of free fetal DNA to determine the fetal RHD status in the U.S.





### **Luis D. Pacheco, MD**

Luis D. Pacheco, MD, is a Professor in the Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine and the Department of Anesthesiology, Division of Surgical Critical Care at the University of Texas Medical Branch in Galveston. Dr. Pacheco completed medical school and his first residency in Obstetrics and Gynecology at the University of Costa Rica. He then completed a second residency in Obstetrics and Gynecology and two fellowships, one in Maternal-Fetal Medicine and the other in Anesthesiology Critical Care, all at the University of Texas Medical Branch in Galveston. He is triple board certified in Obstetrics and Gynecology, Maternal-Fetal Medicine, and Critical Care Medicine. He has written a textbook addressing medical diseases in pregnancy and has directed courses around the United States in similar topics. Dr. Pacheco has written expert opinion papers for the Society for Maternal Fetal Medicine in topics such as amniotic fluid embolism. His research interest is in critical care obstetrics.



### **Michael J. Paidas, MD**

Michael J. Paidas, MD, is Professor and Chair in the Department of Obstetrics, Gynecology and Reproductive Sciences, Miller School of Medicine at the University of Miami, and Chief of Service, University Health Tower, and Jackson Health System. Dr. Paidas received his medical degree from Tufts University School of Medicine and completed his internship and residency in Obstetrics and Gynecology at Pennsylvania Hospital. He completed a Fellowship in Maternal Fetal Medicine at the Mount Sinai School of Medicine in New York. Dr. Paidas is a maternal fetal medicine clinician scientist specializing in reproduction, placenta mediated complications and hemostasis, with activities spanning direct patient care, translational research, and clinical trials. He maintains an independent laboratory and his research has been supported by federal and non-federal agencies, including the NIH. Dr. Paidas' academic profile includes over 500 published manuscripts, abstracts, books, chapters, presentations, and courses.



### **Jason Vaught, MD**

Arthur (Jason) Vaught, MD, is a maternal-fetal medicine and critical care specialist at the Johns Hopkins Hospital in Baltimore, MD. His research studies maternal critical illness, hypertensive disorders of pregnancy, and placenta accreta spectrum. He has been active in the care of both pregnant and non-pregnant patients within the COVID pandemic. His future work focuses on complement inhibition in HELLP syndrome and cardiovascular outcomes after preeclampsia. Dr. Vaught serves on the Medical Advisory Committee for the Foundation for Women & Girls with Blood Disorders (FWGBD).



### **Alisa S. Wolberg, PhD**

Alisa S. Wolberg, PhD (BS '91, PhD '96), is a Professor of Pathology and Laboratory Medicine at the University of North Carolina at Chapel Hill. She currently chairs the ASH Committee on Scientific Affairs, and the NIH/Hemostasis, Thrombosis, Blood Cells, and Transfusion (HTBT) study section. Dr. Wolberg previously served as Associate Editor for *Res Pract in Thromb and Haemost* and is now an Associate Editor of *Blood Advances*. She chaired the 2018 Hemostasis GRC, was Scientific Co-Chair of the ASH 2020 Annual Meeting and is Vice-Chair of the HTRS 2023 meeting and basic science Vice-Chair of the ISTH 2024 meeting. She also directs UNC's T32 "Enhancement training for the next generation of translational Ph.D. scientists" and associated Program in Translational Medicine. Dr. Wolberg's research laboratory studies contributions of fibrin(ogen), factor XIII, and red blood cells to thrombosis, mechanisms in cancer-associated thrombosis and hormone-associated thrombosis, and mechanisms that mediate clot formation and stability in hemophilia and factor XI deficiency.